Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema

NCT07626697 | Active Not Recruiting

• 1 other identifier: 2011-KAEK-50-263
• Study Type: observational
• Target: 81
• Locations: 1 country
• Sites: 1

Brief Summary

Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning. Because these conditions can look alike, distinguishing between them in routine clinical practice may be difficult. This prospective, single-center observational study was designed to compare polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in adult patients with palmoplantar psoriasis and palmoplantar eczema. A total of 81 patients aged 18 years and older were included: 41 patients with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis and 40 patients with palmoplantar eczema. Dermoscopic and UVFD images were evaluated to identify vascular, scaling, surface, and fluorescence-related features that may help differentiate palmoplantar psoriasis from palmoplantar eczema. The study aims to assess whether these non-invasive imaging methods can provide additional diagnostic clues to support clinical evaluation.

Conditions

Palmoplantar Psoriasis; Eczema

Keywords

Palmoplantar eczema; Palmoplantar psoriasis; Dermoscopy; Ultraviolet dermoscopy; UV dermoscopy; Differential diagnosis

Outcome Measures

Primary Outcomes (2)

• Percentage of Participants With Findings on the Predefined Polarized Dermoscopic Feature Checklist Assessed Using DermLite DL5

  Name of measurement: Predefined Polarized Dermoscopic Feature Checklist. Measurement tool: standardized polarized dermoscopic images obtained with a DermLite DL5 handheld dermoscope. Unit of measure: percentage of participants (%). Standardized polarized dermoscopic images will be assessed by blinded independent dermatologists using the checklist. The checklist includes vascular morphology, vascular distribution, scale color, scale distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales. The percentage of participants with each finding will be reported separately for the palmoplantar psoriasis and palmoplantar eczema groups.

  At baseline / single study visit

• Percentage of Participants With Each Predefined Ultraviolet-Induced Fluorescence Dermoscopy Feature Assessed by DermLite DL5

  Unit of measure: percentage of participants (%). Measurement tool: standardized ultraviolet-induced fluorescence dermoscopy (UVFD) images obtained with a DermLite DL5 handheld dermoscope and assessed by blinded independent dermatologists using a predefined UVFD feature checklist. The checklist includes UVFD scale distribution, UVFD scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci. The percentage of participants with each feature will be reported and compared between the palmoplantar psoriasis and palmoplantar eczema groups.

  At baseline / single study visit

Secondary Outcomes (2)

• Cohen's Kappa Coefficient for Interobserver Agreement in Binary and Nominal Dermoscopic and UVFD Feature Assessment

  At baseline / single study visit

• Quadratic Weighted Kappa Coefficient for Interobserver Agreement in Ordinal Dermoscopic and UVFD Feature Assessment

  At baseline / single study visit

Study Arms (2)

Palmoplantar Psoriasis

Patients with clinically and/or histopathologically confirmed palmoplantar psoriasis

Palmoplantar Eczema

Patients with clinically and/or histopathologically confirmed palmoplantar eczema

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A total of 81 adult patients aged 18 years and older with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis or palmoplantar eczema were included. Participants were recruited from the dermatology outpatient clinic of a tertiary care training and research hospital.

You may qualify if:

• Age 18 years or older.
• Clinical diagnosis of palmoplantar psoriasis or palmoplantar eczema involving the palms and/or soles.
• For the palmoplantar psoriasis group: presence of sharply demarcated erythematous and scaly plaques on the palms and/or soles, with diagnosis confirmed clinically and/or histopathologically.
• In clinically uncertain palmoplantar psoriasis cases, at least one supporting feature such as psoriatic lesions outside the palmoplantar area, psoriatic nail involvement, psoriatic arthritis, personal history of psoriasis, or family history of psoriasis.
• For the palmoplantar eczema group: presence of chronic or recurrent palmoplantar eczema with hyperkeratotic and/or fissured palmoplantar plaques, with diagnosis confirmed clinically and/or histopathologically.
• Ability and willingness to provide written informed consent.

You may not qualify if:

• Age younger than 18 years.
• Presence of another palmoplantar dermatosis that may interfere with the diagnosis of palmoplantar psoriasis or palmoplantar eczema.
• Histopathological findings inconsistent with the clinical diagnosis, when histopathological examination was performed.

Sponsors & Collaborators

• Istanbul Training and Research Hospital: lead

Study Sites (1)

Istanbul Training and Research Hospital

Istanbul, Istanbul, 34000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Eczema

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: May 8, 2026
• First Posted: June 4, 2026
• Study Start: November 1, 2025
• Primary Completion: April 20, 2026
• Study Completion: July 31, 2026
• Last Updated: June 4, 2026

Record last verified: 2026-05

Locations

TU (1)